p-hydroxy-phenylglycine amide | 72151-95-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: p-hydroxy-phenylglycine amide
• 英文别名: p-Hydroxyphenylglycinamid；(R)-[[amino(4-hydroxyphenyl)acetyl]amino]；(+)-2-(4-hydroxyphenyl)glycinamide；L(+)-2-(4-hydroxyphenyl)glycinamide；2-Amino-2-(4-hydroxyphenyl)acetamide
• CAS: 72151-95-2
• 化学式: C₈H₁₀N₂O₂
• mdl: MFCD12151950
• 分子量: 166.18
• InChiKey: WQFROZWIRZWMFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  p-hydroxy-phenylglycine amide 在 aminoacylase I from Aspergillus melleus 、 Tris buffer 作用下， 以 水 为溶剂， 反应 1.0h， 生成 L-(+)-对羟基苯甘氨酸
  参考文献：
  名称：

  氨酰酶I在α-氨基酸酯和酰胺的对映选择性拆分中的应用

  摘要：

  来自米曲霉的氨酰基酶I是一种容易获得且便宜的酶，主要用于从其N-乙酰基衍生物工业生产对映纯I-氨基酸，该酶具有高对映选择性，可水解天然和非天然氨基酸的酯和酰胺（对于酯水解，如果酰胺E > 300 ，则E最高为76 ）。酰胺和酯水解的反应速率是可比的，并且在某些情况下，这些转化的进行速度甚至比“传统”氨酰酶催化的N水解更快。因此，β-乙酰基衍生物为拆分相应的外消旋物提供了新的可能性。这种新颖的方法为光学活性氨基酸及其衍生物的生物催化生产提供了另一种途径。

  DOI：

  10.1016/j.tetasy.2004.05.018
• 作为产物：
  描述：

  4-(4-Hydroxy-phenyl)-1,3-oxazolin-2,5-dion 在 ammonium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以78%的产率得到p-hydroxy-phenylglycine amide
  参考文献：
  名称：

  Yongxin, Zhu; Roets, Eugene; Busson, Roger, Bulletin des Societes Chimiques Belges, 1997, vol. 106, # 1, p. 67 - 72

  摘要：

  DOI：

文献信息

• Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
  申请人：G.D. Searle & Co.

  公开号：US20030220521A1

  公开（公告）日：2003-11-27

  Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-&bgr;-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-&bgr;-hydroxylase inhibitors, of which N-acetyl-&ggr;-glutamyl fusaric acid hydrazide (shown below) is preferred. 1

  本文描述了一种肾选择性的前药，其在肾脏中优先转化为能够抑制参与肾交感神经活动的儿茶酚型神经递质合成的化合物。本文所描述的前药来源于能够抑制儿茶酚合成中的一个或多个酶的抑制剂化合物，这些化合物可分类为酪氨酸羟化酶抑制剂，多巴脱羧酶抑制剂或多巴胺-&bgr;-羟化酶抑制剂。这些抑制剂化合物通过可被肾脏中大量存在的酶选择性识别的可裂解键与化学基团（如谷氨酸衍生物）连接。释放的抑制剂化合物然后可在肾脏中用于抑制儿茶酚合成中的一个或多个酶。抑制肾脏儿茶酚合成可抑制与钠潴留相关的疾病（如高血压）相关的增强肾脏神经活动。特别感兴趣的共轭物是多巴胺-&bgr;-羟化酶抑制剂的谷氨酰衍生物，其中N-乙酰-&ggr;-谷氨酰富萨酸肼（如下图所示）是首选。1
• Facile synthesis of 3-oxo-1,2,5-thiadiazoles; 7β-s̆ (3-oxo-1,2,5-thiadiazol-2-yl) cephalosporins
  作者：W.W.H. Lunn、J.K. Shadle

  DOI：10.1016/s0040-4020(01)89437-0

  日期：——

  A simple procedure is described for the preparation of 3-oxo-1,2,5-thiadiazoles under mild conditions. This procedure has provided hitherto unknown 7β-s̆ (3-oxo-1,2,5-thiadiazol-2-yl) cephalosporins.

  描述了在温和条件下制备3-氧代-1,2,5-噻二唑的简单方法。该方法提供了迄今未知的7β-s̆（3-氧代-1,2,5-噻二唑-2-基）头孢菌素。
• Inhibitors of syk and JAK protein kinases
  申请人：Jia Zhaozhong

  公开号：US20100048567A1

  公开（公告）日：2010-02-25

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V的化合物及其互变异构体或药学上可接受的盐、酯和前药，其是syk激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，包含这种化合物的制药组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk激酶活性介导的多种疾病的方法，例如不良血栓和非何杰金淋巴瘤。
• INHIBITORS OF SYK AND JAK PROTEIN KINASES
  申请人：Jia Zhaozhong

  公开号：US20120101275A1

  公开（公告）日：2012-04-26

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V和其互变异构体或药学上可接受的盐、酯和前药的化合物，其为syk激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，含有这种化合物的制药组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk激酶活性介导的多种情况的方法，如非霍奇金淋巴瘤和不良血栓形成。
• Prodrugs
  申请人：MEDIVIR AB

  公开号：US20030186924A1

  公开（公告）日：2003-10-02

  A method for treatment of HBV and HIV infections comprising administering the compound or salt of formula Ig 1

  一种治疗HBV和HIV感染的方法，包括给予化合物或公式Ig1的盐。